Managed Healthcare Executive September 7, 2024
A new review study provides a detailed, long-term comparison at how patients with spinal muscular atrophy (SMA) fared on different therapies, and found that motor function improved across the board, with notable gaps in other health outcomes.
Researchers analyzed data from 21 studies involving 1,374 patients treated with Spinraza (nusinersen), Evrysdi (risdiplam), and Zolgensma (onasemnogene abeparvovec-xioi) for up to 48 months of follow-up. Unlike other studies that have reported clinical results for individual SMA medications, this review synthesizes data about all the approved treatments. Corresponding author Doris Giess, M.B.B.S., M.P.H., of the Austrian Institute for Health Technology and her co-authors said it was first such review of SMA medications.
Giess and her co-authors found that all three therapies were effective...
Today's Sponsors
Today's Sponsor